Effect of bivalirudin +platelet glycoprotein IIbIIIa inhibitors versus heparin + platelet glycoprotein IIbIIIa inhibitors in patients from hospitals in michigan undergoing primary percutaneous coronary intervention

Trial Profile

Effect of bivalirudin +platelet glycoprotein IIbIIIa inhibitors versus heparin + platelet glycoprotein IIbIIIa inhibitors in patients from hospitals in michigan undergoing primary percutaneous coronary intervention

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Bivalirudin (Primary) ; Heparin; Platelet glycoprotein GPIIb IIIa complex inhibitors
  • Indications Haemorrhage; Thrombosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top